Scancell Holdings Plc NewsMakers in the Biotech Industry Conference
September 07 2016 - 1:01AM
RNS Non-Regulatory
TIDMSCLP
Scancell Holdings Plc
07 September 2016
7 September 2016
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell to present at the 23rd Annual NewsMakers in the Biotech
Industry Conference in NYC
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer,
announces that it will be presenting at the 23rd Annual NewsMakers
in the Biotech Industry Conference. The conference is being held on
9 September 2016 at the Millennium Broadway Hotel & Conference
Center in New York City, USA.
Dr John Chiplin, Executive Chairman of Scancell, will be
presenting an overview of the Company at 15:00 ET in presentation
room 311 and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Executive +1 858 900 2646
Chairman Scancell Holdings +44 (0) 20 3727
Dr Richard Goodfellow, CEO Plc 1000
+44 (0) 20 7886
Freddy Crossley (Corporate 2500
Finance) Panmure Gordon & +44 (0) 20 7886
Tom Salvesen (Corporate Broking) Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About NewsMakers in the Biotech Industry Conference
NewsMakers presents a hand-picked group of public biotech
companies whose corporate and regulatory milestones will drive
stock prices. NewsMakers is recognized as the industry's key venue
for companies to take their story to Wall Street each Fall. Thus,
NewsMakers remains the best opportunity for business development
executives and key members of the institutional investment and
analyst communities to compare notes and assess the industry
landscape.
Last year, more than 500 delegates congregated at NewsMakers,
including money managers who controlled more than $480 billion in
equity assets, with over $50 billion dedicated to healthcare and
$15 billion dedicated to biotech.
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUGUBUPQGMQ
(END) Dow Jones Newswires
September 07, 2016 02:01 ET (06:01 GMT)